This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

PD-1/PD-L1 Inhibitors Market

Market Insights on PD-1/PD-L1 Inhibitors covering sales outlook, demand forecast & up-to-date key trends

PD-1/PD-L1 Inhibitors Market By Product (Nivolumab, Pembrolizumab, Atezolizumab, Avelumab and Durvalumab), Indication (Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Cancer, Bladder Cancer, Merkel Cell Carcinoma) & Region - Forecast to 2022 - 2030

PD-1/PD-L1 Inhibitors Market Snapshot (2022-2030)

[209 Pages Report]The global PD-1/PD-L1 inhibitors market is set to record market value of US$ 43.7 Bn in the year 2022 with a CAGR of 10.7% which indicates a positive market growth over the forecast period.

Data Points

Market Insights

Market Value 2022

USD 43.7 Bn

Market Value 2030

USD 98.5 Bn

CAGR 2022-2030

10.7%

Key Players

The key players are Merck & Co., Inc. ,Bristol-Myers Squibb, F. Hoffmann-La Roche AG, AstraZeneca, Pfizer Inc., Merck KGaA

Share of Top 5 Countries             

78.5%

The increasing prevalence of cancer is the key factor for the growth of PD-1 and PD-L1 inhibitors market along with the technological innovations and advancements in cancer screening procedures that are expected to surge market growth. In addition, increased public awareness, greater government initiatives to fight cancer, and rising healthcare expenses are expected to boost the market ahead.

High efficacy and superior treatment outcome based PD-1/PD-L1 inhibitors are on high demand in severe cancer treatments. In addition, extended indications of existing immunotherapies is anticipated to create huge demand for the cancer treatments and offer new growth opportunity in the market.

PD-1/PD-L1 Inhibitors market holds nearly 26% market value share of the US$ 140 Bn oncology drugs market in 2021. Moreover, as early diagnosis remains the cornerstone of cancer control, the rising cancer awareness programs is expected to fuel the support and attention, early diagnosis, and treatment as well as palliative care for population facing cancer diseases.

Driven by this, PD-1/PD-L1 inhibitors market are expected to rise at a 10.7% CAGR over the forecast duration.

Customize this Report

Let us know your requirement to get
100% FREE customization

How The Market Progressed Till June 2022?

Particulars

Details

H1, 2021

13.10%

H1, 2022 Projected

10.71%

H1, 2022 Outlook

9.61%

BPS Change - H1, 2022 (O) – H1, 2022 (P)

(-) 110 ↓

BPS Change – H1, 2022 (O) – H1, 2021

(-) 349 ↓

According to Future Market Insights' analysis, the global PD-1/PD-L1 inhibitors market expects to drop by 349 Basis Point Share (BPS) in H1-2022 as compared to H1- 2021. Whereas in comparison to H1-2022 projected value, the market during H1-2022 outlook period will show a dip of 110 BPS.

The drop in the BPS values is associated with the reported resistance to PD-1/PD-L1 therapy among patients, with only a few estimated to present positive outlook of treatment. With low rates of positive clinical outcomes, the market observed a decline in the associated BPS values owed to the need to develop predictive biomarkers.

The FDA has approved 10 immune checkpoint inhibitors for PD-1/PD-L1 pathway till 2018. The growth of number of FDA approvals for clinical therapy with PD1/PDL1 inhibitors, is expected to provide the market landscape with a positive growth outlook for the forecasted years. For instance, six anti-PD-1/PD-L1 mAbs (monoclonal antibodies) have received approval as of December 2020, with additional indications covering 19 different cancer types and two tissue-agnostic diseases.

Key developments in the market include the development of monoclonal antibodies for targeted therapeutic approaches. The market is subject to changes as per drug trial assessment and regulatory impositions, in accordance to the macro and industry standards.

2015-2021 PD-1/PD-L1 Inhibitors Market Demand Outlook Compared to 2022-2030 forecast

Sales of PD-1/PD-L1 inhibitors market grew at a CAGR of 70.2% between 2015 and 2021.

The primary factor leading to the market growth is a sharp increase in the global prevalence of several cancers together with growing geriatric population across the world, mainly in emerging and developed economies.

For instance, as per the report from the World Health Organization, cancer is a primary cause of death globally. As per the updated release of Globocan report released by the International Agency for Research on Cancer (IARC) in December 2020, the global burden of cancer has risen to 19.3 million cases and deaths by cancer has increased to 10 million in 2020. Hence, the increase in the volume of the patient pool leads to a greater demand for the market driving the growth of the global market during the forecast period.

PD-1/PD-L1 Inhibitors Market Download Report Brochure

Leading industry players are focusing on the development and launch of novel PD-1/PD-L1 inhibitors to treat various types of cancers. This accelerated availability of PD-1/PD-L1 immunotherapeutic in the market is expected to boost the PD-1/PD-L1 inhibitors market.

Considering this, FMI expects the global PD-1/PD-L1 inhibitors market to grow at a CAGR of 10.7% through 2030.

Which Factors Are Restraining Demand for PD-1/PD-L1 Inhibitors?

The high cost of cancer immunotherapy and stringent regulatory scenario are the primary factors hampering the PD-1/PD-L1 inhibitors market over the forecast period.

Cancer treatment cost create significant economic challenges for healthcare providers and patients due to the impact they have on patient safety, quality of care, and overall healthcare. High cost associated with cancer treatment is expected to hamper the treatment adoption rate specially in developing regions.

As biologics progress through clinical trials and to commercialization, the regulatory requirements will become increasingly stringent. Due to the nature of biologics, which are produced by living cells, the process as well as the product must be validated and strictly monitored against critical quality attributes (CQAs) throughout the manufacturing process, not just at the end as for chemistry-based drugs. This creates hurdles to get the regulatory approval for the biologics which limits the market growth.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What is the Impact of the COVID-19 Crisis on the PD-1/PD-L1 Inhibitors Market?

The general impact of COVID-19 on the PD-1/PD-L1 inhibitors market was negative, due to decrease in number of cancer patients visits in clinics and hospitals for PD-1/PD-L1 inhibitors treatment which resulted into drop in the demand for PD-1/PD-L1 inhibitors in 2020.

For instance, as per the NCBI, it was reported that there was about 50% decline in cancer care in U.S., in 2020 and global cancer therapies dropped by 50% during the pandemic. Moreover, WHO released guidelines concerning the nonessential planned therapies like for cancer and procedures on the basis of the demand of critical situations. The guidelines recommended to deliver emergency services to patients who need urgent consideration and postpone the surgery and therapies if not urgent, which resulted into decline in the PD-1/PD-L1 inhibitors market sales.

Country-wise Insights

What Makes the U.S. a Large Market for PD-1/PD-L1 Inhibitors?

The U.S. is estimated to account for around 98.9% of the North America PD-1/PD-L1 inhibitors market in 2022.  

The dominant share of U.S. can mainly be owing to the rising prevalence of several chronic diseases such as lung cancers, urothelial carcinomas, skin cancer, and diabetes over the forecast period in the United States which demanded efficient treatment.

For instance, as per the American Cancer Society report 2020, lung cancer is the second leading cancer resulting into 135,720 deaths men as well as women. The numbers also report that around 84% of all lung cancers are NSCLC (non-small cell lung cancer) and 13% (small cell lung cancer) in the United States which is likely to continue in the coming years leading to greater demand for PD-1/PD-L1 Inhibitors thus, driving the market in the country.

The presence of key manufacturers and large investment in the R&D activities to develop generic drugs and new products together with the government incentives to boost the innovations to reduce the rising disease burden is expected to offer lucrative opportunities for the growth of PD-1/PD-L1 inhibitors market over the forecast period.

Why is Germany Considered a Lucrative PD-1/PD-L1 Inhibitors Market?

Germany is estimated to account for 26.7% of the Europe PD-1/PD-L1 inhibitors market in 2022.

Germany is expected to observe relatively rapid growth compared to other countries in Europe owing to the large number of clinical trials being carried out related to the industry.

Bodies like the European Medicines Agency has increased concentration in the direction of the PD-1/PD-L1 inhibitors with regard to combination therapy and for monotherapy use, focused towards treatment of diseases in adults as well as in trials for use by pediatrics. Also, the growth of the market in Germany can be attributed to the increasing awareness regarding the low toxicity levels and compliance between PD-1/PD-L1 inhibitors and healthcare safety regulations effected by the region.

What are the Factors Fueling the Demand for PD-1/PD-L1 Inhibitors in China?

The PD-1/PD-L1 inhibitors market in China is estimated to be worth US$ 1.8 Bn in 2022 in the global market.

China is expected to display relatively rapid growth rate during the forecast period owing to the large population base, and major investment from private and public sectors into healthcare infrastructure development. In addition, the increase in number of cancer cases, together with the growing interest for immune check point inhibitors is expected to support the development of the market over the forecast period.

Moreover, increasing number of product launches and product innovation in oncology immunotherapy is anticipated to lead the market growth in China.

How will the PD-1/PD-L1 Inhibitors Market Expand across India?

Demand for PD-1/PD-L1 inhibitors in India is expected to rise at around 15.4% CAGR over the forecast period.

The growing incidence of cancer, growing government engagement to surge cancer diagnosis, introduction of new immunotherapies with lesser side effects, and growing adoption of inorganic growth strategies like collaborations, acquisitions, and mergers by major players functioning in the market are the primary factors that are anticipated to fuel the growth of the PD-1/PD-L1 inhibitors market in India during the forecast period.

As per the NCRP (National Cancer Registry Program), India, death of one woman occurs every 8 minutes in India. For every 2 women freshly detected with breast cancer, one out of the two woman dies in India. Moreover, numerous people die daily owing to tobacco-related cancer ailments in India. Tobacco (smokeless and smoked) use accounted for about 317,928 deaths in men as well as women, in 2018.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category-wise Insights

Demand for Pembrolizumab continue gaining Traction

By product, pembrolizumab is anticipated to hold the largest share of 49.5% in 2022, expanding at rate of nearly 10.3% during the forecast period.

Out of all the products of the PD-1/PD-L1 inhibitors market, pembrolizumab is anticipated to observe significant growth owing to the increased adoption of the product over the other products.

The increased adoption of pembrolizumab is owing to its proven effectiveness ever since it’s approval in 2014 to treat various FDA-approved indications such as head and neck squamous cell cancer (HNSCC), non–small cell lung cancer (NSCLC), melanoma, and others. This is boosting the growth of the segment over the forecast period. Large investments by the major players in the development of this product are further driving the sales of the segment over the forecast period.

Why Non-Small Cell Lung Cancer (NSCLC) will hold the most of the market share?

By indication, non-small cell lung cancer (NSCLC) segment will lead the market and is projected to account for 37.0% of the total market revenue share in 2022.

NSCLC (non-small cell lung cancer) holds about 80%-85% of the overall cases of lung cancer worldwide and this major share of non-small cell lung cancer has encouraged the majority of major players to concentrate on continuous innovation of advanced therapeutics and improving the efficacy of the present therapeutics. A growing number of diagnoses of NSCLC (non-small cell lung cancer) and the rising awareness in the nations of the developing and developed markets are supporting the growth of the non-small cell lung cancer segment.

Why Hospital Pharmacies projected maximum growth in the PD-1/PD-L1 Inhibitors Market?

By distribution channel, hospital pharmacies are anticipated to hold the largest share of 48.3% in 2022, expanding at rapid rate of 11.0 % CAGR during the forecast period.

The growth of hospital pharmacies segment is owing to the large scale orders, robust supply chains and attempt by hospital facilities to sustain large scale inventories for cancer therapy applications. In addition, availability of well-developed infrastructure and presence of advanced equipment adds to the development of the segment. Moreover, the growing patient admission in hospitals for cancer treatment is surging the use of PD-1/PD-L1 inhibitors in hospitals, thus boosting the sales in hospital pharmacies.

Competitive Landscape

Companies operating in the PD-1/PD-L1 inhibitors market are moderately competitive by nature, with a presence of several major players. These players are involved in a number of strategic alliances. The agreement and system automation accelerates the manufacturer’s strategy to capitalize on the market share and capture the significant share of market. Some of the recent instances include:

  • In January 2020, Novartis International AG acquired The Medicines Company. This acquisition helped the Novartis in the treatment of the world’s leading cause of mortality and disability with a vaccine-like approach.
  • In October 2021, Merck announced the U.S. Food and Drug Administration (FDA) approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab. The therapy is used for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test.

Scope of the Report

Attribute

Details

Forecast Period

2015-2021

Historical Data Available for

2022-2030

Market Analysis

USD Million for Value

Key Countries Covered

US, Canada, Brazil, Mexico, Argentina, Germany, U.K., France, Italy, Spain, BENELUX, Russia, China, Japan, South Korea, India,  Indonesia, Malaysia, Thailand, Australia, New Zealand, GCC Countries, South Africa, Northern Africa

Key Segments Covered

Product, Indication, Distribution Channel and Region

Key Companies Profiled

Report Coverage

Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives

Customization & Pricing

Available upon Request

PD-1/PD-L1 Inhibitors Market by Category

By Product:

  • Nivolumab
  • Pembrolizumab
  • Atezolizumab
  • Avelumab
  • Durvalumab

By Indication:

  • Melanoma
  • Non-Small Cell Lung Cancer (NSCLC)
  • Renal Cell Carcinoma (RCC)
  • Head and Neck Squamous Cell Cancer (HNSCC)
  • Bladder Cancer
  • Merkel Cell Carcinoma (MCC)
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle-East & Africa

Frequently Asked Questions

The global PD-1/PD-L1 Inhibitors market is worth US$ 36.6 Bn in 2021 and is set to expand 2.3X over the forecast years owing to increasing prevalence of cancer and rising awareness regarding early diagnosis.

The sales of PD-1/PD-L1 Inhibitors in the market have grown at a CAGR of nearly 70.2% between 2015 and 2021.

The PD-1/PD-L1 Inhibitors market is expected to reach US$ 98.5 Bn by the end of 2030 with sales revenue expected to register CAGR of 10.7% over the forecast period.

North America currently holds the largest market share of nearly 55.6% in 2021 of the global market share in PD-1/PD-L1 Inhibitors market with U.S. being the leading contributor with a market value over US$ 20.1 Bn in 20221.

Demand of PD-1/PD-L1 Inhibitors market is expected to register growth in Europe at rate of 11.3% CAGR during the forecast period.

The PD-1/PD-L1 Inhibitors in China is likely to observe growth with an impressive CAGR of 15.0% during the forecast period. China is expected to display relatively rapid growth rate during the forecast period owing to the large population base, and major investment from private and public sectors into healthcare infrastructure development.

Growing burden of cancerous diseases leading to higher adoption of immunotherapy, indication expansion of single biologics across numerous cancer types and increasing industry funding for research driving market growth are key trends driving sales of PD-1/PD-L1 Inhibitors market across the globe.

Japan’s PD-1/PD-L1 Inhibitors market is offering lucrative growth opportunities and is expected to exhibit healthy growth of 14.5% CAGR during the forecast period. South Korea market is expected to exhibit healthy growth of 13.9% CAGR during the forecast period.

U.S., Germany, U.K., France, and China are the top 5 countries that are driving the demand for PD-1/PD-L1 Inhibitors market.

Leading companies of PD-1/PD-L1 Inhibitors are Merck & Co., Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche AG, AstraZeneca, Pfizer Inc., and Merck KGaA

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Technology Roadmap

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Market Background

    4.1. Macro-Economic Factors

        4.1.1. Global GDP Growth Outlook

        4.1.2. Global Healthcare Expenditure Outlook

        4.1.3. Global Pharmaceutical Market

        4.1.4. Global Parent Market Outlook

    4.2. Forecast Factors - Relevance & Impact

        4.2.1. Key Players Historical Growth

        4.2.2. Product Adoption Across Regions

        4.2.3. Product cost

        4.2.4. Growth in drug development

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

5. Market Context

    5.1. Product USPs/ Features

    5.2. ProductAdoption / Usage Analysis

    5.3. Regulatory Scenario

    5.4. Disease Epidemiology, By Key Indication

    5.5. Pipeline Assessment

6. COVID19 Crisis Analysis

    6.1. Current COVID19 Statistics and Probable Future Impact

    6.2. Current GDP Projection and Probable Impact

    6.3. Current Economic Projection as compared to 2008 financial analysis

    6.4. COVID19 and Impact Analysis

        6.4.1. Revenue By Product

        6.4.2. Revenue By Country

    6.5. 2022 Market Scenario

    6.6. Quarter by Quarter Forecast

    6.7. Projected recovery Quarter

7. Global PD-1/PD-L1 Inhibitors Market - Pricing Analysis

    7.1. Regional Pricing Analysis By Product

    7.2. Pricing Break-up

        7.2.1. Manufacturer Level Pricing

        7.2.2. Distributor Level Pricing

    7.3. Global Average Pricing Analysis Benchmark

8. Global PD-1/PD-L1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast, 2022-2030

    8.1. Historical Market Value (US$ Mn) Analysis, 2015-2021

    8.2. Current and Future Market Value (US$ Mn) Projections, 2022-2030

        8.2.1. Y-o-Y Growth Trend Analysis

        8.2.2. Opportunity Analysis, 2022-2030

9. Global PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030, By Product

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Product, 2015–2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2030

        9.3.1. Nivolumab

        9.3.2. Pembrolizumab

        9.3.3. Atezolizumab

        9.3.4. Avelumab

        9.3.5. Durvalumab

    9.4. Market Attractiveness Analysis By Product

10. Global PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030, By Indication

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By Indication, 2015–2021

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022-2030

        10.3.1. Non-Small Cell Lung Cancer (NSCLC)

        10.3.2. Head and Neck Squamous Cell Cancer (HNSCC)

        10.3.3. Bladder Cancer

        10.3.4. Renal Cell Carcinoma (RCC)

        10.3.5. Melanoma

        10.3.6. Merkel Cell Carcinoma (MCC)

        10.3.7. Others

    10.4. Market Attractiveness Analysis By Indication

11. Global PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030, by Distribution Channel

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015–2021

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2030

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Online Pharmacies

    11.4. Market Attractiveness Analysis By Distribution Channel

12. Global PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030, by Region

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Mn) Analysis By Region, 2015–2021

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2030

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. East Asia

        12.3.5. South Asia

        12.3.6. Oceania

        12.3.7. Middle East and Africa

    12.4. Market Attractiveness Analysis By Region

13. North America PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        13.3.1. By Country

            13.3.1.1. U.S.

            13.3.1.2. Canada

        13.3.2. By Product

        13.3.3. By Indication

        13.3.4. By Distribution Channel

    13.4. Market Attractiveness Analysis

    13.5. Key Market Participants - Intensity Mapping

    13.6. Drivers and Restraints - Impact Analysis

14. Latin America PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021

    14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        14.3.1. By Country

            14.3.1.1. Brazil

            14.3.1.2. Mexico

            14.3.1.3. Argentina

            14.3.1.4. Rest of Latin America

        14.3.2. By Product

        14.3.3. By Indication

        14.3.4. By Distribution Channel

    14.4. Market Attractiveness Analysis

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

15. Europe PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021

    15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        15.3.1. By Country

            15.3.1.1. Germany

            15.3.1.2. Italy

            15.3.1.3. France

            15.3.1.4. U.K.

            15.3.1.5. Spain

            15.3.1.6. BENELUX

            15.3.1.7. Russia

            15.3.1.8. Rest of Europe

        15.3.2. By Product

        15.3.3. By Indication

        15.3.4. By Distribution Channel

    15.4. Market Attractiveness Analysis

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

16. South Asia PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021

    16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        16.3.1. By Country

            16.3.1.1. India

            16.3.1.2. Thailand

            16.3.1.3. Indonesia

            16.3.1.4. Malaysia

            16.3.1.5. Rest of South Asia

        16.3.2. By Product

        16.3.3. By Indication

        16.3.4. By Distribution Channel

    16.4. Market Attractiveness Analysis

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

17. East Asia PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021

    17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        17.3.1. By Country

            17.3.1.1. China

            17.3.1.2. Japan

            17.3.1.3. South Korea

        17.3.2. By Product

        17.3.3. By Indication

        17.3.4. By Distribution Channel

    17.4. Market Attractiveness Analysis

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

18. Oceania PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021

    18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        18.3.1. By Country

            18.3.1.1. Australia

            18.3.1.2. New Zealand

        18.3.2. By Product

        18.3.3. By Indication

        18.3.4. By Distribution Channel

    18.4. Market Attractiveness Analysis

    18.5. Key Market Participants - Intensity Mapping

    18.6. Drivers and Restraints - Impact Analysis

19. Middle East and Africa PD-1/PD-L1 Inhibitors Market Analysis 2015-2021 and Forecast 2022-2030

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021

    19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        19.3.1. By Country

            19.3.1.1. GCC Countries

            19.3.1.2. Turkey

            19.3.1.3. South Africa

            19.3.1.4. Rest of Middle East and Africa

        19.3.2. By Product

        19.3.3. By Indication

        19.3.4. By Distribution Channel

    19.4. Market Attractiveness Analysis

    19.5. Key Market Participants - Intensity Mapping

    19.6. Drivers and Restraints - Impact Analysis

20. Key and Emerging Countries PD-1/PD-L1 Inhibitors Market Analysis 2022 & 2030

    20.1. Introduction

        20.1.1. Market Value Proportion Analysis, By Key Countries

        20.1.2. Global Vs. Country Growth Comparison

    20.2. U.S. PD-1/PD-L1 Inhibitors Market Analysis

        20.2.1. By Product

        20.2.2. By Indication

        20.2.3. By Distribution Channel

    20.3. Canada PD-1/PD-L1 Inhibitors Market Analysis

        20.3.1. By Product

        20.3.2. By Indication

        20.3.3. By Distribution Channel

    20.4. Mexico PD-1/PD-L1 Inhibitors Market Analysis

        20.4.1. By Product

        20.4.2. By Indication

        20.4.3. By Distribution Channel

    20.5. Brazil PD-1/PD-L1 Inhibitors Market Analysis

        20.5.1. By Product

        20.5.2. By Indication

        20.5.3. By Distribution Channel

    20.6. U.K. PD-1/PD-L1 Inhibitors Market Analysis

        20.6.1. By Product

        20.6.2. By Indication

        20.6.3. By Distribution Channel

    20.7. Germany PD-1/PD-L1 Inhibitors Market Analysis

        20.7.1. By Product

        20.7.2. By Indication

        20.7.3. By Distribution Channel

    20.8. France PD-1/PD-L1 Inhibitors Market Analysis

        20.8.1. By Product

        20.8.2. By Indication

        20.8.3. By Distribution Channel

    20.9. Italy PD-1/PD-L1 Inhibitors Market Analysis

        20.9.1. By Product

        20.9.2. By Indication

        20.9.3. By Distribution Channel

    20.10. Spain PD-1/PD-L1 Inhibitors Market Analysis

        20.10.1. By Product

        20.10.2. By Indication

        20.10.3. By Distribution Channel

    20.11. BENELUX PD-1/PD-L1 Inhibitors Market Analysis

        20.11.1. By Product

        20.11.2. By Indication

        20.11.3. By Distribution Channel

    20.12. Russia PD-1/PD-L1 Inhibitors Market Analysis

        20.12.1. By Product

        20.12.2. By Indication

        20.12.3. By Distribution Channel

    20.13. China PD-1/PD-L1 Inhibitors Market Analysis

        20.13.1. By Product

        20.13.2. By Indication

        20.13.3. By Distribution Channel

    20.14. Japan PD-1/PD-L1 Inhibitors Market Analysis

        20.14.1. By Product

        20.14.2. By Indication

        20.14.3. By Distribution Channel

    20.15. South Korea PD-1/PD-L1 Inhibitors Market Analysis

        20.15.1. By Product

        20.15.2. By Indication

        20.15.3. By Distribution Channel

    20.16. India PD-1/PD-L1 Inhibitors Market Analysis

        20.16.1. By Product

        20.16.2. By Indication

        20.16.3. By Distribution Channel

    20.17. ASEAN PD-1/PD-L1 Inhibitors Market Analysis

        20.17.1. By Product

        20.17.2. By Indication

        20.17.3. By Distribution Channel

    20.18. Australia PD-1/PD-L1 Inhibitors Market Analysis

        20.18.1. By Product

        20.18.2. By Indication

        20.18.3. By Distribution Channel

    20.19. New Zealand PD-1/PD-L1 Inhibitors Market Analysis

        20.19.1. By Product

        20.19.2. By Indication

        20.19.3. By Distribution Channel

    20.20. GCC Countries PD-1/PD-L1 Inhibitors Market Analysis

        20.20.1. By Product

        20.20.2. By Indication

        20.20.3. By Distribution Channel

    20.21. Turkey PD-1/PD-L1 Inhibitors Market Analysis

        20.21.1. By Product

        20.21.2. By Indication

        20.21.3. By Distribution Channel

    20.22. South Africa PD-1/PD-L1 Inhibitors Market Analysis

        20.22.1. By Product

        20.22.2. By Indication

        20.22.3. By Distribution Channel

21. Market Structure Analysis

    21.1. Market Analysis by Tier of Companies

    21.2. Market Share Analysis of Top Players (2021)

    21.3. Market Presence Analysis

        21.3.1. Regional Footprint by Players

        21.3.2. Product Foot print by Players

22. Competition Analysis

    22.1. Competition Dashboard

    22.2. Competition Benchmarking

    22.3. Competition Deep Dive (Tentative List)

        22.3.1. Bristol-Myers Squibb Company

            22.3.1.1. Overview

            22.3.1.2. Product Portfolio

            22.3.1.3. Profitability by Market Segments (Product/Channel/Region)

            22.3.1.4. Sales Footprint

            22.3.1.5. SWOT Analysis

            22.3.1.6. Strategy Overview

                22.3.1.6.1. Marketing Strategy

                22.3.1.6.2. Product Strategy

                22.3.1.6.3. Channel Strategy

        22.3.2. Eli Lilly and Company

            22.3.2.1. Overview

            22.3.2.2. Product Portfolio

            22.3.2.3. Profitability by Market Segments (Product/Channel/Region)

            22.3.2.4. Sales Footprint

            22.3.2.5. SWOT Analysis

            22.3.2.6. Strategy Overview

                22.3.2.6.1. Marketing Strategy

                22.3.2.6.2. Product Strategy

                22.3.2.6.3. Channel Strategy

        22.3.3. F.Hoffman-La Roche AG

            22.3.3.1. Overview

            22.3.3.2. Product Portfolio

            22.3.3.3. Profitability by Market Segments (Product/Channel/Region)

            22.3.3.4. Sales Footprint

            22.3.3.5. SWOT Analysis

            22.3.3.6. Strategy Overview

                22.3.3.6.1. Marketing Strategy

                22.3.3.6.2. Product Strategy

                22.3.3.6.3. Channel Strategy

        22.3.4. AstraZeneca Plc

            22.3.4.1. Overview

            22.3.4.2. Product Portfolio

            22.3.4.3. Profitability by Market Segments (Product/Channel/Region)

            22.3.4.4. Sales Footprint

            22.3.4.5. SWOT Analysis

            22.3.4.6. Strategy Overview

                22.3.4.6.1. Marketing Strategy

                22.3.4.6.2. Product Strategy

                22.3.4.6.3. Channel Strategy

        22.3.5. Pfizer Inc

            22.3.5.1. Overview

            22.3.5.2. Product Portfolio

            22.3.5.3. Profitability by Market Segments (Product/Channel/Region)

            22.3.5.4. Sales Footprint

            22.3.5.5. SWOT Analysis

            22.3.5.6. Strategy Overview

                22.3.5.6.1. Marketing Strategy

                22.3.5.6.2. Product Strategy

                22.3.5.6.3. Channel Strategy

        22.3.6. Merck KGaA.

            22.3.6.1. Overview

            22.3.6.2. Product Portfolio

            22.3.6.3. Profitability by Market Segments (Product/Channel/Region)

            22.3.6.4. Sales Footprint

            22.3.6.5. SWOT Analysis

            22.3.6.6. Strategy Overview

                22.3.6.6.1. Marketing Strategy

                22.3.6.6.2. Product Strategy

                22.3.6.6.3. Channel Strategy

23. Assumptions and Acronyms Used

24. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global PD-1/PDL-1 Inhibitors Market Analysis 2015-2021 and Forecast 2022–2030, By Product

Table 02: Global PD-1/PDL-1 Inhibitors Market Analysis 2015-2021 and Forecast 2022–2030, By Indication

Table 03: Global PD-1/PDL-1 Inhibitors Market Analysis 2015-2021 and Forecast 2022–2030, By Distribution Channel

Table 04: Global PD-1/PDL-1 Inhibitors Market Analysis 2015-2021 and Forecast 2022–2030, By Region

Table 05: North America PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015–2021 and Forecast 2022–2030, By Country

Table 06: North America PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Product

Table 07: North America PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Indication

Table 08: North America PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Distribution Channel

Table 09: Latin America PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015–2021 and Forecast 2022–2030, By Country

Table 10: Latin America PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Product

Table 11: Latin America PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Indication

Table 12: Latin America PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Distribution Channel

Table 13: Europe PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015–2021 and Forecast 2022–2030, By Country

Table 14: Europe PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Product

Table 15: Europe PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Indication

Table 16: Europe PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Distribution Channel

Table 17: South Asia PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015–2021 and Forecast 2022–2030, By Country

Table 18: South Asia PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Product

Table 19: South Asia PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Indication

Table 20: South Asia PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Distribution Channel

Table 21: East Asia PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015–2021 and Forecast 2022–2030, By Country

Table 22: East Asia PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Product

Table 23: East Asia PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Indication

Table 24: East Asia PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Distribution Channel

Table 25: Oceania PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015–2021 and Forecast 2022–2030, By Country

Table 26: Oceania PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Product

Table 27: Middle East and Africa PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015–2021 and Forecast 2022–2030, By Country

Table 28: Middle East and Africa PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Product

Table 29: Middle East and Africa PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Indication

Table 30: Middle East and Africa PD-1/PDL-1 Inhibitors Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022–2030, By Distribution Channe

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global PD-1/PDL-1 Inhibitors Market Value Analysis, 2015–2021

Figure 02: Global PD-1/PDL-1 Inhibitors Market Forecast & Y-o-Y Growth, 2022–2030

Figure 03: Global PD-1/PDL-1 Inhibitors Market Absolute $ Opportunity (US$ Mn) Analysis, 2021–2030

Figure 04: Global PD-1/PDL-1 Inhibitors Market Y-o-Y Growth (%) Analysis, 2021–2030

Figure 05: Global PD-1/PDL-1 Inhibitors Market Value Share (%) Analysis 2022 & 2030, By Product

Figure 06: Global PD-1/PDL-1 Inhibitors Market Y-o-Y Growth (%) Analysis 2021-2030, By Product

Figure 07: Global PD-1/PDL-1 Inhibitors Market Attractiveness Analysis 2022–2030, By Product

Figure 08: Global PD-1/PDL-1 Inhibitors Market Value Share (%) Analysis 2022 & 2030, By Indication

Figure 09: Global PD-1/PDL-1 Inhibitors Market Y-o-Y Growth (%) Analysis 2021-2030, By Indication

Figure 10: Global PD-1/PDL-1 Inhibitors Market Attractiveness Analysis 2022–2030, By Indication

Figure 11: Global PD-1/PDL-1 Inhibitors Market Value Share (%) Analysis 2022 & 2030, By Distribution Channel

Figure 12: Global PD-1/PDL-1 Inhibitors Market Y-o-Y Growth (%) Analysis 2021-2030, By Distribution Channel

Figure 13: Global PD-1/PDL-1 Inhibitors Market Attractiveness Analysis 2022–2030, By Distribution Channel

Figure 14: Global PD-1/PDL-1 Inhibitors Market Value Share (%) Analysis 2022 & 2030, By Region

Figure 15: Global PD-1/PDL-1 Inhibitors Market Y-o-Y Growth (%) Analysis 2021-2030, By Region

Figure 16: Global PD-1/PDL-1 Inhibitors Market Attractiveness Analysis 2022–2030, By Region

Figure 17: North America PD-1/PDL-1 Inhibitors Market Value Analysis, 2015–2021

Figure 18: North America PD-1/PDL-1 Inhibitors Market Forecast & Y-o-Y growth, 2022–2030

Figure 19: North America PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Product

Figure 20: North America PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Indication

Figure 21: North America PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Distribution Channel

Figure 22: North America PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Country

Figure 23: Latin America PD-1/PDL-1 Inhibitors Market Value Analysis, 2015–2021

Figure 24: Latin America PD-1/PDL-1 Inhibitors Market Forecast & Y-o-Y growth, 2022–2030

Figure 25: Latin America PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Product

Figure 26: Latin America PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Indication

Figure 27: Latin America PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Distribution Channel

Figure 28: Latin America PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Country

Figure 29: Europe PD-1/PDL-1 Inhibitors Market Value Analysis, 2015–2021

Figure 30: Europe PD-1/PDL-1 Inhibitors Market Forecast & Y-o-Y growth, 2022–2030

Figure 31: Europe PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Product

Figure 32: Europe PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Indication

Figure 33: Europe PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Distribution Channel

Figure 34: Europe PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Country

Figure 35: South Asia PD-1/PDL-1 Inhibitors Market Value Analysis, 2015–2021

Figure 36: South Asia PD-1/PDL-1 Inhibitors Market Forecast & Y-o-Y growth, 2022–2030

Figure 37: South Asia PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Product

Figure 38: South Asia PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Indication

Figure 39: South Asia PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Distribution Channel

Figure 40: South Asia PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Country

Figure 41: East Asia PD-1/PDL-1 Inhibitors Market Value Analysis, 2015–2021

Figure 42: East Asia PD-1/PDL-1 Inhibitors Market Forecast & Y-o-Y growth, 2022–2030

Figure 43: East Asia PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Product

Figure 44: East Asia PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Indication

Figure 45: East Asia PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Distribution Channel

Figure 46: East Asia PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Country

Figure 47: Oceania PD-1/PDL-1 Inhibitors Market Value Analysis, 2015–2021

Figure 48: Oceania PD-1/PDL-1 Inhibitors Market Forecast & Y-o-Y growth, 2022–2030

Figure 49: Oceania PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Product

Figure 50: Oceania PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Indication

Figure 51: Oceania PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Distribution Channel

Figure 52: Oceania PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Country

Figure 53: Middle East and Africa PD-1/PDL-1 Inhibitors Market Value Analysis, 2015–2021 

Figure 54: Middle East and Africa PD-1/PDL-1 Inhibitors Market Forecast & Y-o-Y growth, 2022–2030

Figure 55: Middle East and Africa PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Product

Figure 56: Middle East and Africa PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Indication

Figure 57: Middle East and Africa PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Distribution Channel

Figure 58: Middle East and Africa PD-1/PDL-1 Inhibitors Market Attractiveness Analysis, By Country

Figure 59: U.S. PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 60: U.S. PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 61: U.S. PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 62: Canada PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 63: Canada PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 64: Canada PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 65: Mexico PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 66: Mexico PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 67: Mexico PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 68: Brazil PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 69: Brazil PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 70: Brazil PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 71: U.K. PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 72: U.K. PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 73: U.K. PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 74: Germany PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 75: Germany PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 76: Germany PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 77: France PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 78: France PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 79: France PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 80: Italy PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 81: Italy PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 82: Italy PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 83: Russia PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 84: Russia PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 85: Russia PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 86: China PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 87: China PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 88: China PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 89: Japan PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 90: Japan PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 91: Japan PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 92: South Korea PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 93: South Korea PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 94: South Korea PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 95: India PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 96: India PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 97: India PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 98: Australia PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 99: Australia PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 100: Australia PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 101: New Zealand PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 102: New Zealand PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 103: New Zealand PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 104: GCC Countries PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 105: GCC Countries PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 106: GCC Countries PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Figure 107: South Africa PD-1/PDL-1 Inhibitors Market Share Analysis (%), 2022E & 2030F

Figure 108: South Africa PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Product, 2022E

Figure 109: South Africa PD-1/PDL-1 Inhibitors Market Share Analysis (%), By Indication, 2022E

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Cancer Tissue Diagnostics Market

Published : March 2021

Healthcare

Brain Cancer Diagnostics Market

Published : December 2016

Healthcare

Cancer Diagnostics Market

Published : March 2021

Healthcare

Lung Cancer Surgery Market

Published : January 2022

Google translate

PD-1/PD-L1 Inhibitors Market